成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Crenolanib

別名: CP-868596, ARO 002 中文名稱:克萊拉尼

Crenolanib是一種有效的,選擇性PDGFRα/β抑制劑,在CHO細胞中Kd為2.1 nM/3.2 nM,也能有效抑制FLT3,對D842V突變型敏感對V561D突變型不敏感,作用于PDGFR比作用于c-Kit,VEGFR-2,TIE-2,F(xiàn)GFR-2,EGFR,erbB2,和Src的選擇性高100倍以上。Crenolanib可輔助誘導(dǎo)線粒體自噬。

Crenolanib Chemical Structure

Crenolanib Chemical Structure

CAS: 670220-88-9

規(guī)格 價格 庫存 購買數(shù)量
10mM (1mL in DMSO) 1542.83 現(xiàn)貨
5mg 1385.13 現(xiàn)貨
10mg 2623.19 現(xiàn)貨
50mg 7929.23 現(xiàn)貨
1g 32678.1 現(xiàn)貨
更大包裝 有超大折扣

400-668-6834

info@selleck.cn

免費分裝
免費預(yù)溶

Crenolanib相關(guān)產(chǎn)品

相關(guān)信號通路圖

細胞實驗數(shù)據(jù)示例

細胞系 實驗類型 給藥濃度 孵育時間 活性描述 文獻信息
A549 cells Cell viability assay 3.9-1000 nM 72 h a dose-dependent inhibition of cancer cell viability 25328409
MV4-11 Cytotoxicity assay 0.5 to 5000 nM 2 to 8 hrs Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability at 0.5 to 5000 nM incubated for 2 to 8 hrs followed by compound washout by CellTiter-Glo luminescent assay 30742435
MV4-11 Cytotoxicity assay 72 hrs Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability incubated for 72 hrs by CellTiter-Blue assay, IC50=0.012μM 30742435
MV4-11 Function assay a decrease in mitochondrial matrix protein aconitase hydratase 2 (ACO2) 25328409
MV4-11 Cytotoxicity assay Cytotoxicity against human MV4-11 cells expressing FLT3 ITD mutant, IC50=0.0015μM 31207462
MOLM13 Cytotoxicity assay Cytotoxicity against human MOLM13 cells expressing FLT3 ITD mutant, IC50=0.0049μM 31207462
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
點擊查看更多細胞系數(shù)據(jù)

生物活性

產(chǎn)品描述 Crenolanib是一種有效的,選擇性PDGFRα/β抑制劑,在CHO細胞中Kd為2.1 nM/3.2 nM,也能有效抑制FLT3,對D842V突變型敏感對V561D突變型不敏感,作用于PDGFR比作用于c-Kit,VEGFR-2,TIE-2,F(xiàn)GFR-2,EGFR,erbB2,和Src的選擇性高100倍以上。Crenolanib可輔助誘導(dǎo)線粒體自噬。
靶點
FLT3 [1]
(CHO cells)
PDGFRα [1]
(CHO cells)
PDGFRβ [1]
(CHO cells)
0.74 nM(Kd) 2.1 nM(Kd) 3.2 nM(Kd)
體外研究(In Vitro)
體外研究活性

Crenolanib顯著有效,能夠抑制耐藥的PDGFRα激酶(D842I,D842V,D842Y,D1842-843IM,和缺失I843)活性。Crenolanib作用于同基因模型系統(tǒng)中D842V,IC50大約為10 nM。Crenolanib抑制EOL-1細胞中融合致癌基因的激酶活性,其衍生自慢性噬酸細胞白血病患者,且表達持續(xù)活化的FIP1L1- PDGFRα融合激酶,IC50 = 21 nM。Crenolanib也會抑制EOL-1細胞的增殖,IC50 = 0.2 pM。Crenolanib抑制在BaF3細胞中表達的V561D或D842V突變激酶的活化,IC50分別為85 nM或272 nM。Crenolanib抑制H1703非小細胞肺癌細胞系中PDGFRα活化,其能夠使包含PDGFRα基因座的4q12區(qū)域擴增24倍,IC50為26 nM。[1]

Crenolanib是一種口服具有生物活性的,高度有效的,選擇性PDGFR TKI。Crenolanib是苯并咪唑化合物,對PDGFRA和PDGFRB的IC50s分別為0.9 nM和1.8 nM。[2]

激酶實驗 PDGFRα激酶活性的生物化學(xué)評估
中國倉鼠卵巢(CHO)細胞用突變型或野生型PDGFRα瞬時轉(zhuǎn)染,用不同濃度的Crenolanib處理。涉及重組DNA的實驗使用2級生物安全條件,根據(jù)指南進行。制備來自細胞系的蛋白質(zhì)裂解物,使用抗PDGFRα抗體進行免疫沉淀反應(yīng),然后用于PDGFRα的連續(xù)免疫印跡。使用Photoshop軟件進行密度測定以量化藥物作用,磷酸-PDGFRα的水平標(biāo)歸一化到總蛋白質(zhì)。密度測定法和增殖實驗結(jié)果使用Calcusyn 2.1軟件分析,以精確測定IC50值。使用Wilcoxon Rank Sum Test比較Crenolanib對給定突變體的IC50值。
細胞實驗 細胞系 EOL-1 細胞系
濃度 0-20 pM
孵育時間 72小時
方法

將細胞以20, 000細胞/孔的密度加入96孔板,與Crenolanib培育72小時,然后使用2,3-bis[2-甲氧基-4-硝基-5-磺苯基]-2H-四唑-5-羰基苯胺 (XTT)-試驗測量細胞增殖。

實驗圖片 檢測方法 檢測指標(biāo) 實驗圖片 PMID
Western blot pKIT / KIT pFLT3 / FLT3 / pERK / ERK / pS6 / S6 pAKT / AKT / pMAPK / MAPK / pSTAT5 / STAT5 24623852
Growth inhibition assay Cell viability 24623852
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00949624 Completed
Advanced Solid Tumors
Arog Pharmaceuticals Inc.
December 2005 Phase 1

化學(xué)信息&溶解度

分子量 443.54 分子式

C26H29N5O2

CAS號 670220-88-9 SDF Download Crenolanib SDF
Smiles CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
儲存條件(自收到貨起)

體外溶解度
批次:

DMSO : 88 mg/mL ( (198.4 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO)

Ethanol : 88 mg/mL (198.4 mM)

Water : Insoluble

摩爾濃度計算器

體內(nèi)溶解度
批次:

現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑

動物體內(nèi)配方計算器

實驗計算

摩爾濃度計算器

質(zhì)量 濃度 體積 分子量

動物體內(nèi)配方計算器(澄清溶液)

第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)

mg/kg g μL

第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結(jié)果:

工作液濃度: mg/ml;

DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);

體內(nèi)配方配制方法:μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。

體內(nèi)配方配制方法:μL DMSO母液,加入μL Corn oil,混勻澄清。

注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。

操作手冊

如果有其他問題,請給我們留言。

* 必填項

請輸入您的姓名
請輸入您的郵箱地址 請輸入一個有效的郵箱地址
請寫點東西給我們
Tags: buy Crenolanib | Crenolanib supplier | purchase Crenolanib | Crenolanib cost | Crenolanib manufacturer | order Crenolanib | Crenolanib distributor
在線咨詢
聯(lián)系我們